ISSN 1006-298X      CN 32-1425/R

Chinese Journal of Nephrology, Dialysis & Transplantation ›› 2018, Vol. 27 ›› Issue (6): 570-575.DOI: 10.3969/j.issn.1006-298X.2018.06.016

• Article • Previous Articles     Next Articles

Nephrotoxicity of anti vascular endothelial growth factor therapy

  

  • Online:2018-12-28 Published:2019-01-21

Abstract:

Anti vascular endothelial growth factor (VEGF) and VEGF receptor  target agents is not rare.The most common were proteinuria and hypertension,and the worst is thrombotic microangiopathy (TMA).All of these were induced via interfering the normal physiological of VEGF in kidney.The pathological characteristics was varied,TMA was prominent in monoclinic antibody treatment patients,and for minimal change disease/focal segmental glomerulosclerosis lesion were more common in tyrosine kinase inhibitors.The pathogenesis of the two lesions were not the same.Renal insufficiency and dialysis was not the contraindication,most drugs can be used,and the curative effect matched patients without renal dysfunction.